CAMBRIDGE, Massachusetts and TORONTO, Ontario , Aug. 06, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody ...
An update from ProMIS Neurosciences ( (PMN) ) is now available.
TORONTO, Ontario and CAMBRIDGE, Massachusetts , Sept. 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development ...
Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through ...
ProMIS Neurosciences Inc., a biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases, announced progress in its clinical programs and shared insights from its ...
View ProMIS Neurosciences Inc. PMN stock quote prices, financial information, real-time forecasts, and company news from CNN.
"2024 was a transformational year for ProMIS Neurosciences as we reached a major milestone with the initiation of our 100-patient Phase 1b clinical trial for PMN310, our lead antibody candidate for AD ...
In a recent transaction, Neil Cashman, the Chief Scientific Officer of ProMIS Neurosciences Inc. (NASDAQ:PMN), acquired 15,000 common shares of the company at $0.973 per share. The purchase comes as ...
) has been revised to $137.06 / share. This is an increase of 2,288.89% from the prior estimate of $5.74 dated November 14, 2025. The price target is an average of many targets provided by analysts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results